Bionano Genomics shares surge 10.88% premarket after Q3 revenue jumps 21%, gross margin hits 46%, and operating expenses drop 40%.

Bionano Genomics surged 10.88% in premarket trading following the release of its Q3 2025 earnings report, which highlighted a 21% year-over-year revenue increase to $7.4 million, driven by 7% growth in flow cell sales and a 15% rise in higher-margin consumables and software revenue. The company reported a 46% non-GAAP gross margin (up from 26% in Q3 2024) and a 40% reduction in operating expenses to $9.7 million. A $10 million public offering in September 2025 bolstered its cash reserves to $31.8 million, while management reiterated full-year 2025 revenue guidance of $26–$30 million and raised Q4 expectations to $7.5–$7.9 million. Strategic focus on consumables/utilization and progress in securing OGM reimbursement (including a new CPT code) further reinforced investor confidence in the firm’s operational turnaround and long-term growth potential.